ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

n-dodecyl .beta.-d-maltoside

Its studies are mostly in Non-Muscle Invasive Bladder Neoplasms, led by Pfizer.

Furthest: phase 1, since Sep 25, 20251 company-led study, 1 open or runningNext primary completion: Jan 29, 2030 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer11 open or runningphase 1since Sep 25, 2025Sep 25, 2025Jan 29, 2030phase 1 · NCT07206225

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 25, 2025First study: phase 1 study in Non-Muscle Invasive Bladder NeoplasmsFirst studyNCT07206225 · 294 planned · United States, France, Israel and more

Ahead

  1. Jan 29, 2030Primary completion: phase 1 study in Non-Muscle Invasive Bladder NeoplasmsNCT07206225

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07206225Non-Muscle Invasive Bladder Neoplasms · United States, France, Israel and more1RecruitingJan 29, 2030294

How it is read

Names in the registry

  • “PF-02921367”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.